| John D Andenoro, MD | |
|
350 Heritage Way Ste 2300, Kalispell, MT 59901-3167 | |
| (406) 752-8456 | |
| (406) 752-1443 |
| Full Name | John D Andenoro |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 28 Years |
| Location | 350 Heritage Way Ste 2300, Kalispell, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518058551 | NPI | - | NPPES |
| 0038488 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 9848 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kalispell Regional Medical Center | Kalispell, MT | Hospital |
| North Valley Hospital | Whitefish, MT | Hospital |
| Cabinet Peaks Medical Center | Libby, MT | Hospital |
| St. Patrick Hospital | Missoula, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Rockies Medical Center, Inc. | 0345234506 | 10 |
| Kalispell Regional Medical Center Inc | 5294644381 | 354 |
News Archive
New results are in from the Women's Health Initiative (WHI) Calcium plus Vitamin D Supplementation Trial. These findings assess the effects on hip fracture and colorectal cancer incidence among 30,000 postmenopausal women nearly five years after the seven-year period of calcium plus vitamin D supplementation ended.
Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.
Health officials in the Philippines have issued a warning to the public regarding the crucifixion and self-flagellation rituals which abound at Easter.
› Verified 7 days ago
| Entity Name | Kalispell Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235333139 PECOS PAC ID: 5294644381 Enrollment ID: O20031122000142 |
News Archive
New results are in from the Women's Health Initiative (WHI) Calcium plus Vitamin D Supplementation Trial. These findings assess the effects on hip fracture and colorectal cancer incidence among 30,000 postmenopausal women nearly five years after the seven-year period of calcium plus vitamin D supplementation ended.
Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.
Health officials in the Philippines have issued a warning to the public regarding the crucifixion and self-flagellation rituals which abound at Easter.
› Verified 7 days ago
| Entity Name | Urology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891886867 PECOS PAC ID: 3274527726 Enrollment ID: O20040408001236 |
News Archive
New results are in from the Women's Health Initiative (WHI) Calcium plus Vitamin D Supplementation Trial. These findings assess the effects on hip fracture and colorectal cancer incidence among 30,000 postmenopausal women nearly five years after the seven-year period of calcium plus vitamin D supplementation ended.
Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.
Health officials in the Philippines have issued a warning to the public regarding the crucifixion and self-flagellation rituals which abound at Easter.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John D Andenoro, MD 350 Heritage Way Ste 2300, Kalispell, MT 59901-3167 Ph: (406) 752-8456 | John D Andenoro, MD 350 Heritage Way Ste 2300, Kalispell, MT 59901-3167 Ph: (406) 752-8456 |
News Archive
New results are in from the Women's Health Initiative (WHI) Calcium plus Vitamin D Supplementation Trial. These findings assess the effects on hip fracture and colorectal cancer incidence among 30,000 postmenopausal women nearly five years after the seven-year period of calcium plus vitamin D supplementation ended.
Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.
Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.
Health officials in the Philippines have issued a warning to the public regarding the crucifixion and self-flagellation rituals which abound at Easter.
› Verified 7 days ago
Dr. Jerrod Tyler Heermans, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 350 Heritage Way Ste 2300, Kalispell, MT 59901 Phone: 406-890-7432 Fax: 406-890-7402 | |
Sarabeth Lee Martin, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 350 Heritage Way Ste 2300, Kalispell, MT 59901 Phone: 406-890-7432 | |
Dr. Gregory Thomas Adams, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 350 Heritage Way, 2300, Kalispell, MT 59901 Phone: 406-752-8456 Fax: 406-755-1088 | |
Amy K Mckerrow, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 350 Heritage Way, Suite 2300, Kalispell, MT 59901 Phone: 406-752-8456 Fax: 406-752-1443 | |
Michael J Berson, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 169 Sunset Trl, Kalispell, MT 59901 Phone: 406-257-6888 | |
Dr. Craig Grinnell Hinman, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 625 7th Ave E, Kalispell, MT 59901 Phone: 509-590-6827 |